Improvised cardiac function of siddha formulation Sikkanjar elixir® through CAMK2 and VEGF mechanism-in experimentally induced cardiac hypertrophy model in rats.
5 affiliations
- 1Department of Research and Development, Earth India Naturals, Tiruvannamalai, TN, India. Electronic address: [email protected].
- 2Department of Research and Development, Earth India Naturals, Tiruvannamalai, TN, India. Electronic address: [email protected].
- 3Department of Research and Development, Earth India Naturals, Tiruvannamalai, TN, India. Electronic address: [email protected].
- 4Department of Pharmacology, PSG College of Pharmacy, Coimbatore, TN, India. Electronic address: [email protected].
- 5Department of Pharmacology, PSG College of Pharmacy, Coimbatore, TN, India. Electronic address: [email protected].
Abstract
Background
Sikkanjar elixir® (SE) contains 29 herbs, honey and fermented rice water. It is a modified and fortified form of Sikkanjar Manappagu (Manappagu means syrup), a Siddha traditional medicine. SE has its reference to treat vascular block, high cholesterol, varicose vein, hypertension; improved cardiac efficiency and blood circulation. However, the validation of Siddha claim of SE has not been carried out in experimentally conditions.Objective
The present study designed to validate the scientific claim of SE and investigate the cardio-protective prospective of SE, in a rat model of cardiac hypertrophy (CH).Materials and methods
CH was induced in Sprague-Dawley rats via ligation of the descending abdominal aorta. The cardio-protective effects of SE were evaluated through behavioral assessments, biochemical parameters, antioxidant profiling, liver and kidney function tests, ATP, troponin I levels measurement. The cardiac hypertrophy markers like CAMK2, VEGF, and SIRT3 expression were measured through qRTPCR.Results
HPTLC evaluation of SE denotes 1.221 mg RUE/g and 4.604 mg GAE/g, of total flavonoid and phenolics content respectively. CH induction led to elevated heart rate, troponin I, and liver/kidney function markers, along with decreased plasma glucose, cholesterol, tissue ATP, catalase, glutathione, and VEGF levels. SE treatment significantly reversed these changes, as evidenced by reduced heart rate, normalization of biochemical markers, and improved antioxidant status. Notably, SE treatment suppressed CAMK2 expression and upregulated VEGF, suggesting enhanced myocardial contractility. Histopathological analysis further supported these findings, showing reduced myocyte fibre thickness and septal volume.Conclusion
SE reversed the CH induced pathology through restoration of cardiac pumping efficiency (ejection fraction) via CAMK2 and VEGF mechanism. Normalization of cardiac output might contribute to the recovery of kidney, metabolic functions and promotion of anti-oxidant effect. These observations can also be extrapolated in CCF or MI conditions in clinical situations.
Related
- Mechanism-informed machine learning for interpretable drug release prediction and virtual formulation intervention in polymeric long-acting injectables
- Glutamine Metabolism in Cardiac Hypertrophy
- Deep Gluteal Syndrome and Persistent Sciatica in a Patient With Unilateral Piriformis Muscle Hypertrophy: A Case Report
- Not every right-atrial mass is a myxoma: infiltrative right-atrial lipomatous hypertrophy treated with debulking and patch reconstruction
- Association of adipocyte hypertrophy and ultrasound severity score in lymphedematous limb: a cross-sectional study
BibTeX
@article{adaikalam2026improvised,
title = {{Improvised cardiac function of siddha formulation Sikkanjar elixir® through CAMK2 and VEGF mechanism-in experimentally induced cardiac hypertrophy model in rats.}},
author = {S Joseph Maria Adaikalam and J Tejasri and R Arunagiri and B Naveen Kumar and M Ramanathan},
journal = {Journal of Ayurveda and integrative medicine},
year = {2026},
month = sep,
doi = {10.1016/j.jaim.2026.101402},
url = {https://europepmc.org/article/MED/42863203},
note = {CC BY},
}
RIS
TY - JOUR
TI - Improvised cardiac function of siddha formulation Sikkanjar elixir® through CAMK2 and VEGF mechanism-in experimentally induced cardiac hypertrophy model in rats.
AU - S Joseph Maria Adaikalam
AU - J Tejasri
AU - R Arunagiri
AU - B Naveen Kumar
AU - M Ramanathan
PY - 2026
DA - 2026/09/01
JO - Journal of Ayurveda and integrative medicine
DO - 10.1016/j.jaim.2026.101402
UR - https://europepmc.org/article/MED/42863203
AB - Background Sikkanjar elixir® (SE) contains 29 herbs, honey and fermented rice water. It is a modified and fortified form of Sikkanjar Manappagu (Manappagu means syrup), a Siddha traditional medicine. SE has its reference to treat vascular block, high cholesterol, varicose vein, hypertension; improved cardiac efficiency and blood circulation. However, the validation of Siddha claim of SE has not been carried out in experimentally conditions.Objective The present study designed to validate the scientific claim of SE and investigate the cardio-protective prospective of SE, in a rat model of cardiac hypertrophy (CH).Materials and methods CH was induced in Sprague-Dawley rats via ligation of the descending abdominal aorta. The cardio-protective effects of SE were evaluated through behavioral assessments, biochemical parameters, antioxidant profiling, liver and kidney function tests, ATP, troponin I levels measurement. The cardiac hypertrophy markers like CAMK2, VEGF, and SIRT3 expression were measured through qRTPCR.Results HPTLC evaluation of SE denotes 1.221 mg RUE/g and 4.604 mg GAE/g, of total flavonoid and phenolics content respectively. CH induction led to elevated heart rate, troponin I, and liver/kidney function markers, along with decreased plasma glucose, cholesterol, tissue ATP, catalase, glutathione, and VEGF levels. SE treatment significantly reversed these changes, as evidenced by reduced heart rate, normalization of biochemical markers, and improved antioxidant status. Notably, SE treatment suppressed CAMK2 expression and upregulated VEGF, suggesting enhanced myocardial contractility. Histopathological analysis further supported these findings, showing reduced myocyte fibre thickness and septal volume.Conclusion SE reversed the CH induced pathology through restoration of cardiac pumping efficiency (ejection fraction) via CAMK2 and VEGF mechanism. Normalization of cardiac output might contribute to the recovery of kidney, metabolic functions and promotion of anti-oxidant effect. These observations can also be extrapolated in CCF or MI conditions in clinical situations.
SN - 0975-9476
SN - 0976-2809
ER -